Rituxan (rituximab) - Roche
Is Antibody Clearance Enough? Immunologic Remission Frequently Fails to Translate into Proteinuria Resolution in Phospholipase A2 Receptor (PLA2R)-Associated Membranous Nephropathy (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0810; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Rituximab use was significantly higher among immunological responders (60% vs. 34%, p=0.009)...Dependence on current ELISA–only thresholds (<14 RU/mL) may overestimate antibody clearance; adding negative immunofluorescence improves complete remission prediction. These findings challenge current surrogate endpoints and underscore the need to recalibrate immunological remission definitions in MN." 
Clinical • Chronic Kidney Disease • Glomerulonephritis • Renal Disease
https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4558828
 
Nilang G. Patel; Naman Gupta; Scott Silvey; Jason M. Kidd; Ambarish Athavale
 
Oct 2, 2026
 
Prev Next